Asset Details
Do you wish to reserve the book?
Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults
Do you wish to request the book?
Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults
2016
Overview
An investigational subunit vaccine containing the varicella-zoster virus (VZV) glycoprotein E (gE) and the AS01B adjuvant system is being evaluated for the prevention of herpes zoster (HZ) in older adults. A phase II trial evaluating different formulations of this vaccine (containing 25μg, 50μg, or 100μg gE) was conducted in adults ≥60 years of age and showed that all formulations elicited robust cellular and humoral immune responses for up to 3 years after vaccination. In this follow-up study in subjects who received two doses of the 50μg gE/AS01B formulation (HZ/su), we assessed the persistence of the immune responses for up to 6 years after vaccination.
This phase II, open-label, multicenter, single-group trial conducted in the Czech Republic, Germany, Sweden, and the Netherlands followed 129 subjects who had received two doses (2 months apart) of HZ/su during the initial trial. Vaccine-induced immune responses (frequencies of gE-specific CD4+ T cells expressing ≥2 activation markers and serum anti-gE antibody concentrations) were evaluated at 48, 60, and 72 months after the first HZ/su dose.
Six years after vaccination with HZ/su, gE-specific cell-mediated immune responses and anti-gE antibody concentrations had decreased by 20–25% from month 36, but remained higher than the prevaccination values. At month 72, the gE-specific cell-mediated immune response was 3.8 times higher than the prevaccination value (477.3 vs. 119.4 activated gE-specific CD4+ T cells per 106 cells), and the anti-gE antibody concentration was 7.3 times higher than the prevaccination value (8159.0 vs. 1121.3mIU/mL). No vaccine-related serious adverse events were reported between months 36 and 72.
gE-specific cellular and humoral immune responses persisted for 6 years after two-dose vaccination with HZ/su in healthy older adults. No safety concerns were identified.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Age
/ Aged
/ Antigens
/ CD4-Positive T-Lymphocytes - immunology
/ elderly
/ Female
/ Germany
/ Herpes Zoster - prevention & control
/ Herpes Zoster Vaccine - immunology
/ Herpes Zoster Vaccine - therapeutic use
/ Humans
/ Lipid A - administration & dosage
/ Lipid A - analogs & derivatives
/ Male
/ Saponins - administration & dosage
/ Sweden
/ Vaccines
/ Vaccines, Subunit - immunology
